Taysha Gene Therapies, Inc.
TSHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001806310
In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Taysha Gene Therapies, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 109
- +22 vs. Q4 2023
- Shares held
- 140.2M
- +10.0M (+7.7%) vs. Q4 2023
- Total value
- $402.2M
- +$171.9M (+74.6%) vs. Q4 2023
- New holders
- 36
- 29 more added
- Sold out
- 14
- 27 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TSHA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 208 | $2.03B |
| Q1 2026 | 191 | $1.18B |
| Q4 2025 | 195 | $1.48B |
| Q3 2025 | 155 | $865.6M |
| Q2 2025 | 150 | $595.4M |
| Q1 2025 | 127 | $232.0M |
| Q4 2024 | 131 | $289.8M |
| Q3 2024 | 119 | $315.5M |
| Q2 2024 | 107 | $354.3M |
| Q1 2024 | 109 | $402.2M |
| Q4 2023 | 87 | $230.3M |
| Q3 2023 | 63 | $410.6M |
| Q2 2023 | 39 | $9.05M |
| Q1 2023 | 44 | $13.3M |
| Q4 2022 | 52 | $43.8M |
| Q3 2022 | 54 | $27.0M |
| Q2 2022 | 59 | $54.7M |
| Q1 2022 | 71 | $110.9M |
| Q4 2021 | 65 | $215.6M |
| Q3 2021 | 48 | $361.9M |
| Q2 2021 | 49 | $388.6M |
| Q1 2021 | 46 | $358.5M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Taysha Gene Therapies, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tybourne Capital Management (HK) Ltd | 3,700,000 | $10.6M | 1.82% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 4,004,756 | $11.5M | 0.14% | 00.0% | Unchanged |
| Morgan Stanley | 5,168,890 | $14.8M | 0.00% | +4,952,352+2,287.1% | Added |
| Vanguard Group Inc | 5,917,414 | $17.0M | 0.00% | −278,153−4.5% | Reduced |
| VR Adviser, LLC | 9,000,000 | $25.8M | 1.23% | −1,412,872−13.6% | Reduced |
| Ra Capital Management, L.P. | 10,872,503 | $31.2M | 0.40% | −7,600,000−41.1% | Reduced |
| RTW Investments, LP | 18,593,185 | $53.4M | 0.79% | +1,700,000+10.1% | Added |
| Avoro Capital Advisors LLC | 18,650,000 | $53.5M | 0.62% | +14,294,445+328.2% | Added |
| FMR LLC | 20,110,717 | $57.7M | 0.00% | −2,328,407−10.4% | Reduced |
| TCG Crossover Management, LLC | 0 | $0 | 0.00% | −2,912,861−100.0% | Sold out |
| Exome Asset Management LLC | 0 | $0 | 0.00% | −693,300−100.0% | Sold out |
| Monaco Asset Management SAM | 0 | $0 | 0.00% | −295,000−100.0% | Sold out |
| Polar Asset Management Partners Inc. | 0 | $0 | 0.00% | −186,700−100.0% | Sold out |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −58,140−100.0% | Sold out |
| Redwood Wealth Management Group, LLC | 0 | $0 | 0.00% | −42,600−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −28,477−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −26,070−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −17,389−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −17,202−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −12,032−100.0% | Sold out |
| Camelot Portfolios, LLC | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| Royal Capital Wealth Management, LLC | 0 | $0 | 0.00% | −10,665−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −50−100.0% | Sold out |